Kala Pharmaceuticals, Inc. (0JQ2.L)
USD 3.75
(0.01%)
USD 3.75
(0.01%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 39.15 Million USD | -53.02% |
| 2022 | 82.68 Million USD | -29.07% |
| 2021 | 116.57 Million USD | 17.26% |
| 2020 | 99.42 Million USD | 7.73% |
| 2019 | 92.29 Million USD | 42.6% |
| 2018 | 64.72 Million USD | 62.31% |
| 2017 | 39.87 Million USD | 22.06% |
| 2016 | 32.66 Million USD | 104.3% |
| 2015 | 15.99 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 11.7 Million USD | 26.28% |
| 2024 Q2 | 9.57 Million USD | -18.23% |
| 2023 Q1 | 10.06 Million USD | 9.96% |
| 2023 Q3 | 10.5 Million USD | 13.7% |
| 2023 Q2 | 9.24 Million USD | -8.21% |
| 2023 FY | 38.85 Million USD | -53.02% |
| 2023 Q4 | 9.27 Million USD | -11.76% |
| 2022 FY | 82.68 Million USD | -29.07% |
| 2022 Q4 | 9.15 Million USD | -38.73% |
| 2022 Q3 | 14.94 Million USD | -44.96% |
| 2022 Q2 | 27.14 Million USD | -13.68% |
| 2022 Q1 | 31.44 Million USD | 18.94% |
| 2021 Q1 | 30.82 Million USD | 3.22% |
| 2021 Q3 | 28.23 Million USD | -9.17% |
| 2021 Q4 | 26.44 Million USD | -6.34% |
| 2021 Q2 | 31.08 Million USD | 0.83% |
| 2021 FY | 116.57 Million USD | 17.26% |
| 2020 Q2 | 21.35 Million USD | 2.46% |
| 2020 Q4 | 29.86 Million USD | 9.14% |
| 2020 Q1 | 20.84 Million USD | 1.03% |
| 2020 FY | 99.42 Million USD | 7.73% |
| 2020 Q3 | 27.36 Million USD | 28.13% |
| 2019 Q1 | 25.19 Million USD | 6.9% |
| 2019 FY | 92.29 Million USD | 42.6% |
| 2019 Q4 | 20.63 Million USD | -7.7% |
| 2019 Q3 | 22.35 Million USD | -7.32% |
| 2019 Q2 | 24.11 Million USD | -4.29% |
| 2018 Q2 | 14.51 Million USD | 30.34% |
| 2018 Q1 | 11.13 Million USD | -0.01% |
| 2018 Q3 | 15.49 Million USD | 6.73% |
| 2018 Q4 | 23.56 Million USD | 52.09% |
| 2018 FY | 64.72 Million USD | 62.31% |
| 2017 Q1 | 9.57 Million USD | -4.15% |
| 2017 Q2 | 9.63 Million USD | 0.62% |
| 2017 FY | 39.87 Million USD | 22.06% |
| 2017 Q4 | 11.14 Million USD | 16.84% |
| 2017 Q3 | 9.53 Million USD | -1.0% |
| 2016 Q4 | 9.98 Million USD | 2.44% |
| 2016 Q2 | 7.86 Million USD | 54.87% |
| 2016 Q1 | 5.07 Million USD | 0.0% |
| 2016 Q3 | 9.74 Million USD | 23.99% |
| 2016 FY | 32.66 Million USD | 104.3% |
| 2015 FY | 15.99 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 99.618% |
| Dynavax Technologies Corporation | 219.14 Million USD | 82.134% |
| Illumina, Inc. | 3.81 Billion USD | 98.973% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 98.093% |
| Biogen Inc. | 5.2 Billion USD | 99.248% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 91.318% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 96.406% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 97.123% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 92.599% |
| Waters Corporation | 943.51 Million USD | 95.85% |
| Perrigo Company plc | 1.52 Billion USD | 97.438% |
| uniQure N.V. | 285.08 Million USD | 86.266% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 90.423% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 90.845% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 85.798% |
| bluebird bio, Inc. | 240.23 Million USD | 83.702% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 72.517% |
| Imunon, Inc. | 21.03 Million USD | -86.173% |
| Myriad Genetics, Inc. | 600.1 Million USD | 93.476% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 97.548% |
| Nektar Therapeutics | 190.9 Million USD | 79.491% |
| Editas Medicine, Inc. | 247.3 Million USD | 84.168% |
| Verastem, Inc. | 92.08 Million USD | 57.481% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.904% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -181.481% |
| Heron Therapeutics, Inc. | 120.65 Million USD | 67.55% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 12.345% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 97.758% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 82.879% |
| Evolus, Inc. | 189.75 Million USD | 79.367% |
| Adicet Bio, Inc. | 152.03 Million USD | 74.248% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -222.486% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 98.609% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 85.6% |
| FibroGen, Inc. | 398.11 Million USD | 90.165% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 98.149% |
| OPKO Health, Inc. | 574.68 Million USD | 93.187% |
| Homology Medicines, Inc. | 9.87 Million USD | -296.486% |
| Geron Corporation | 70.44 Million USD | 44.417% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 97.825% |
| Exelixis, Inc. | 1.58 Billion USD | 97.533% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 61.168% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 29.778% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 92.901% |
| Zoetis Inc. | 2.76 Billion USD | 98.584% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 91.781% |
| Abeona Therapeutics Inc. | 48.5 Million USD | 19.275% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.18% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 94.978% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 89.378% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 86.919% |
| Blueprint Medicines Corporation | 722.86 Million USD | 94.584% |
| Insmed Incorporated | 949.26 Million USD | 95.875% |
| TG Therapeutics, Inc. | 198.47 Million USD | 80.273% |
| Incyte Corporation | 1.19 Billion USD | 96.711% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 96.25% |